“…Tauopathies are divided into primary tauopathies in which tau is the predominant protein abnormality and secondary tauopathies in which tau protein aggregates coexist with other protein abnormalities. Primary tauopathies include PSP, CBD, FTD with parkinsonism linked to chromosome 17 (FTDP-17), behavioral variant FTD, primary progressive aphasia (PPA; predominantly nonfluent forms), Pick’s disease (PiD), chronic traumatic encephalopathy (CTE), argyrophilic grain disease (AGD), aging-related tau astrogliopathy (ARTAG), globular glia tauopathy (GGT), tangle only dementia (TOD), and primary age-related tauopathy (PART) (Table 1 ) [ 21 , 40 , 57 , 70 , 74 , 83 , 90 ]. Together these primary tauopathies affect millions of individuals with no currently available therapeutic alternatives that address the primary tau-related pathology and concomitant progressive neuronal degeneration [ 98 ].…”